Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hello gyus,
Anybody know Paion.
Puls Check
Good Morning all,
Anybody knows when the Hearing is???
- There are over 2000 furnaces at Mesa, each valued at about $500K which GTAT will sell over time and Apple will get a percentage of the sales. Apple's monetary claim appears to be limited to a percentage of the sale of equipment at Mesa. (i.e. no claw back into other GTAT assets)
What Say L2
if the debt is gone then the bk will be cancelled?????
Which mean:
60,4% are in hands
And 39,6 in freefloat?????
Is this true???
http://www.sec.gov/Archives/edgar/data/1420720/000114420414059693/v390550_s1.htm#a_007
How Many Shares are free?
as of the last proxy for ibio ken dart's eastern capital owned:
Eastern Capital Limited 23,744,000 (3) 36.0 %
3) Consists of 21,960,000 shares of common stock and warrants to purchase 1,784,000 shares of common stock held by Eastern. This information is based solely on information set forth in a Schedule 13D/A Amendment No. 3 filed with the SEC on October 18, 2013 by Eastern, Portfolio Services Ltd. and Kenneth B. Dart.
Ibio latest proxy statement
Wehre can i find bid/ask realtime
Ty
insert-text-here
Traders Get Bullish on Shares of Peregrine Pharmaceuticals, Shares Up 14.5% (PPHM)
Written ob Wed, 10/15/2014 - 11:46am
By Nick Russo
Peregrine Pharmaceuticals (NASDAQ:PPHM) is one of today's best performing low-priced stocks, up 14.5% to $1.60 on 6.4x average daily volume. Peregrine Pharmaceuticals has traded 5.7 million shares thus far today, vs. average volume of 885,000 shares per day. The stock has outperformed the Dow (14.5% to the Dow's -1.2%) and outperformed the S&P 500 (14.5% to the S&P's -1.2%) during today's trading.
There is potential upside of 159.9% for shares of Peregrine Pharmaceuticals based on a current price of $1.60 and an average consensus analyst price target of $4.17. The stock should find resistance at its 200-day moving average (MA) of $1.73, as well as support at its 50-day MA of $1.52.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the research, development and commercialization of novel therapeutics for cancer and a wide range of viral diseases.
Peregrine Pharmaceuticals share prices have moved between a 52-week high of $3.18 and a 52-week low of $1.16 and are now trading 38% above that low price at $1.60 per share. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 0.7%.
SmarTrend recommended that its subscribers protect gains by selling shares of Peregrine Pharmaceuticals on March 26th, 2014 by issuing a Downtrend alert when the shares were trading at $1.92. Since that call, shares of Peregrine Pharmaceuticals have fallen 27.1%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.
iBio Inc (NYSEMKT:IBIO) signed a long-term license and collaboration agreement with CalibeBiotherapeutics. According to this agreementiBioLaunch technology would be utilized for the production of biologic drugs in the manufacturing facility of Caliber. The agreement between the two companies wold allow partnership with third parties for the production ofbiotherapeutics and vaccines.
ZMapp- Highly Effective For Ebola Treatment:
ZMapp, the drug for the treatment of Ebola was originally produced by Mapp Biopharmaceutical Inc. which is a privately owned company. ZMappis, by far, the most advanced experimental Ebola drug. The drug that iBio is developing is a combinationof three monoclonal antibodies. It was used recently to treat two American health workers who were infected by Ebola virus in Liberia.
All supplies of the ZMapp have been exhausted. The US Department of Health and Human Services is trying to work things out with iBio Inc. to find a suitable way for the manufacturing of sufficient doses of the drug.ZMapp is produced in tobacco plants and it involves an extremely lengthy process that can take up to several months to complete. Before the news about iBio having ZMapp in hands was surfaced, it was speculated that the Health Department was engaged in talks with Caliber Biotherapeutics.
Caliber Biotherapeutics Collaboration with A&M:
Caliber Biotherapeutics is currently working in collaboration with the Texas A&M Health Science Center for Innovation in Advanced Development and Manufacturing. It is one of the three biodefense centers in the United States. An official of A&M stated that the center is in contact with the Health Department continuously in regards to using thecapabilitiesof Caliber for Less
they were going to close down seeking alpha
What do. you mein?
Dont understand
The gab is closed.
Go higher ibio
Gab is closed?
This ar More buys.
And with 100 piece down ???
The gab is still closing
Wehre is the gab?
1,7 or 1,5???
insert-text-here
"Gretchen Michael, spokeswoman for HHS' Office of the Assistant Secretary for Preparedness and Response, says the government agency is also in talks with Texas-based Caliber Biotherapeutics about producing more ZMapp, along with Kentucky BioProcessing. Caliber says on its website it has the "world's largest plant-made pharmaceutical facility." Caliber officials wouldn't comment on how discussions are going."
3POWER and Seawind expect to close the merger as soon as 2010 audited financial statements are completed. A detailed summary of the terms of the merger and additional disclosures are expected to be filed with the U.S. Securities and Exchange Commission shortly.
ok sorry
Hi guys
sorry for my english:
i think i know why Rudana decrease from 69% to 51,1%
Strategic Investment Agreement with Bangkok Solar Power Co., Ltd.
On May 21, 2010, the Company entered into a Strategic Investment Agreement (the “Agreement”) with Bangkok Solar Power Co., Ltd. (“BSP”), a leading manufacturer of PV solar modules and engineering, procurement, construction, and installation (“EPCI”) contractor to acquire up to 6,639,063 shares of the Company’s Common Stock. All shares issued to BSP will be subject to a lock-up period until December 31, 2013.
correct me if i am wrong